PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 5272 (107th)

Prescription Drug Fair Competition Act of 2002

referredUnited States· United States Congress· EN

Introduced

26 July 2002

Last action

29 July 2002 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Sen. Brown, Sherrod [D-OH], Rep. Waxman, Henry A. [D-CA-24], Rep. McDermott, Jim [D-WA-7], NITA LOWEY, Rep. Rivers, Lynn N. [D-MI-13], Rep. Olver, John W. [D-MA-1], Rep. Ross, Mike [D-AR-4], Rep. Wexler, Robert [D-FL-19], Rep. Barcia, James A. [D-MI-5], Betty McCollum, Rep. Kildee, Dale E. [D-MI-7], Sen. Schiff, Adam B. [D-CA], Rep. Baird, Brian [D-WA-3], Rep. Barrett, Thomas M. [D-WI-5], Rep. Frank, Barney [D-MA-4], Rep. Thurman, Karen L. [D-FL-5], CAROLYN MALONEY, Rep. McCarthy, Karen [D-MO-5], Rep. Filner, Bob [D-CA-51], Rep. Payne, Donald M. [D-NJ-10], Rep. Abercrombie, Neil [D-HI-1]

Subjects

Healthcare

Source updated

19 August 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Prescription Drug Fair Competition Act of 2002 - Amends the Federal Food, Drug, and Cosmetic Act to revise provisions concerning the timing of generic drug availability. Requires applicants (pharmaceutical companies) to register their patents with the Food and Drug Administration (FDA) within 30 days of approval (or issuance for subsequently issued patents). Makes failure to timely register a bar to civil actions for patent infringement. Requires applications for new drugs (NDA) or abbreviated new drug applications (ANDA) which rely upon investigations not conducted by or for the applicant and which concern a patent that claims both the drug and a method of use or more than one method of use to include a certification on a claim-by-claim basis that the patent is invalid or will not be infringed (known as a Paragraph IV filing/certification) by the new drug's (generic) manufacture and a statement regarding the method(s) of use claim. Prohibits (for subsequently issued patents) an extension of the 30 month stay of FDA approval for any new drug where an ANDA or NDA contains a Paragraph IV filing/certification and the patent holder indicates an intention to bring a patent infringement suit against the new (generic) drug's manufacturer. Makes failure to timely file a civil action for infringement a bar to later action. Requires the first generic applicant with a Paragraph IV filing to forfeit the 180 day marketing exclusivity period to a subsequent generic applicant if the first generic applicant engages in certain behaviors which delay or prevent the marketing of the generic drug. Revises notice requirements for Paragraph IV filings to include and protect certain proposed formulation, composition, or method of use information. Excludes an applicants's ability to pay damages from a court's consideration of whether or not to provide injunctive relief before the expiration of the 30 month stay of approval period.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 26 July 2002

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 26 July 2002

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 26 July 2002

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 29 July 2002

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.